Tyrosine Kinase Inhibitor

Treatment with immediate release tablets of a non-covalent Bruton’s tyrosine kinase inhibitor for relapsing forms of multiple sclerosis met pharmacokinetic and pharmacodynamic goals, data show.

Early response to ponatinib appeared predictive of survival among certain patients with chronic myeloid leukemia, according to findings presented at Society of Hematologic Oncology Annual Meeting.

Healio spoke with Charu Aggarwal, MD, MPH, about data from the Keynote-789 trial presented at this year’s ASCO Annual Meeting.

In this video, George Martin, MD, discusses highlights in the treatment of psoriasis

CHICAGO — Patients diagnosed with stage IV non-small cell lung cancer who received a tyrosine kinase inhibitor following clinical molecular testing had better OS, according to research presented at ASCO Annual Meeting.

Genentech announced positive results from its global phase 2 study evaluating the investigational oral Bruton’s tyrosine kinase inhibitor fenebrutinib in adults with relapsing forms of MS.

In this Healio video exclusive, Jashin J. Wu, MD, FAAD, covers a presentation from the American Academy of Dermatology Annual Meeting on TAK-279, a tyrosine kinase 2 inhibitor, in the treatment of individuals with severe psoriasis.

Healio spoke with Rishi P. Singh, MD, about treatments in the pipeline for diabetic macular edema.

The emergence of drugs inhibiting the JAK-STAT pathway has culminated in tyrosine kinase 2 inhibitors targeting psoriatic arthritis, lupus and other indications, noted a presenter at the 2022 Association of Women in Rheumatology conference.

Remibrutinib reduced the need for rescue medication and improved symptoms among patients with chronic spontaneous urticaria, according to a study presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress.